Providers/Grant Support
This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Credits Available
- Physicians — maximum of 0.5 AMA PRA Category 1 CreditsTM
All other healthcare professionals completing this course will be issued a statement of participation
Target Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Program Overview
From the 2025 Fall Clinical Dermatology Conference®, experts Dr. Raj Chovatiya and Dr. Boni Elewski dive into the pathophysiology of GPP and apply the latest data on IL-36 inhibitors to achieve effective disease management. Tune in to this short Seminar-in-Depth to hear how they managed challenging patient cases.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Review the underlying pathophysiological mechanisms of generalized pustular psoriasis (GPP) that impact clinical presentation and disease course
- Apply clinical data for approved and emerging IL-36 inhibitors to the long-term management of GPP
Faculty
Raj Chovatiya, MD, PhD, MSCI
Associate Professor, Rosalind Franklin University of Medicine and Science, Chicago Medical School; Founder and Director,
Center for Medical Dermatology + Immunology Research,
Chicago, IL
Boni Elewski, MD
James Elder Professor and Chair of Dermatology,
University of Alabama at Birmingham,
Birmingham, AL
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
Faculty Name
Raj Chovatiya, MD, PhD, MSCI
Consultant: AbbVie, Arcutis, Arena, Argenx, Beiersdorf, Bristol Myers Squibb, Dermavant, Eli Lilly and Company, EPI Health, Incyte, LEO Pharma, L’Oréal, National Eczema Association, Pfizer Inc., Regeneron, Sanofi, and UCB
Speakers’ Bureau or Honoraria: AbbVie, Arcutis, Dermavant, Eli Lilly and Company, Incyte, LEO Pharma, Pfizer Inc., Regeneron, Sanofi, and UCB
Boni E. Elewski, MD
Grant/Research Support: Ortho Dermatology
Consultant: Ortho Dermatology
The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.
Instructions For Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be immediately available to the participant.
Disclosure of Unlabeled Use
The Institute requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For CME questions please contact: [email protected]